We previously reported that 4-hydroxytamoxifen (Tam), the active metabolite of tamoxifen, induces the expression of IGFBP-1 in a GPER1-dependent manner in MCF-7 breast cancer cells (Vaziri-Gohar & Houston 2016). Here, GPER1 is linked to breast carcinoma.